| ID | 1122 |
| Name of the vaccine | ViVaxim |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 16 years and older |
| Description of the vaccine | Combined purified Vi polysaccharide typhoid and inactivated Hepatitis A vaccine. |
| Name of the manufacturer | Sanofi Pasteur Ltd |
| Name of the manufacturing country | Canada |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Clear liquid |
| Dosage | Dose - 1 mL. Single dose for initial protection. Repeat vaccinations are required to maintain protection every 3 years. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Active immunization to prevent typhoid fever and hepatitis A. |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For hepatitis A. |
| Side effects of vaccine | Redness, pain, swelling, headache, feeling unwell, soreness, muscle ache, nausea, fever and fainting. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=643&keywords=typhoid |
| Other name | NA |
| Additional Links | https://www.nps.org.au/medicine-finder/vivaxim-solution-for-injection
|